Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course.
CD20
IgG
MS
anti-B-cell
deficiency
immunoglobulines
low
multiple sclerosis
prevalence
Journal
Therapeutic advances in neurological disorders
ISSN: 1756-2856
Titre abrégé: Ther Adv Neurol Disord
Pays: England
ID NLM: 101480242
Informations de publication
Date de publication:
2019
2019
Historique:
received:
28
01
2019
accepted:
18
08
2019
entrez:
22
10
2019
pubmed:
22
10
2019
medline:
22
10
2019
Statut:
epublish
Résumé
In multiple sclerosis (MS), the frequency of hypogammaglobulinemia is unknown. We aimed to evaluate the frequency of reduced immunoglobulin (Ig) concentrations and its association with immunotherapy and disease course in two independent MS cohorts. In our retrospective cross-sectional study, MS patients and control patients with head or neck pain from Bern University Hospital (Bern, Switzerland) and Eginition University Hospital (Athens, Greece) were included. The lower limits of normal (LLN) for serum Ig concentration were IgG < 700 mg/dl, IgM < 40 mg/dl, and IgA < 70 mg/dl. Mann-Whitney In total, 327 MS patients were retrospectively identified (Bern/Athens: Our study demonstrated high prevalence rates of reduced serum IgG concentrations in MS patients with and without disease-modifying treatments. The significance of lower IgG concentrations at the levels noted is unclear considering that infections or interference with antibody production generally occur when IgG levels are much lower, at or below 400 mg/dl. However, the information is useful to monitor IgG levels especially with anti-B-cell therapies and consider IgG substitution when levels drop below 400 mg/dl.
Sections du résumé
BACKGROUND
BACKGROUND
In multiple sclerosis (MS), the frequency of hypogammaglobulinemia is unknown. We aimed to evaluate the frequency of reduced immunoglobulin (Ig) concentrations and its association with immunotherapy and disease course in two independent MS cohorts.
METHODS
METHODS
In our retrospective cross-sectional study, MS patients and control patients with head or neck pain from Bern University Hospital (Bern, Switzerland) and Eginition University Hospital (Athens, Greece) were included. The lower limits of normal (LLN) for serum Ig concentration were IgG < 700 mg/dl, IgM < 40 mg/dl, and IgA < 70 mg/dl. Mann-Whitney
RESULTS
RESULTS
In total, 327 MS patients were retrospectively identified (Bern/Athens:
CONCLUSION
CONCLUSIONS
Our study demonstrated high prevalence rates of reduced serum IgG concentrations in MS patients with and without disease-modifying treatments. The significance of lower IgG concentrations at the levels noted is unclear considering that infections or interference with antibody production generally occur when IgG levels are much lower, at or below 400 mg/dl. However, the information is useful to monitor IgG levels especially with anti-B-cell therapies and consider IgG substitution when levels drop below 400 mg/dl.
Identifiants
pubmed: 31632461
doi: 10.1177/1756286419878340
pii: 10.1177_1756286419878340
pmc: PMC6767745
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1756286419878340Informations de copyright
© The Author(s), 2019.
Déclaration de conflit d'intérêts
Conflict of interest statement: G Zoehner, A Miclea, N Kamber, C Friedli, F Ahmadi, M Bagnoud, and N Sédille-Mostafaie report no disclosures. A Salmen received speaker honoraria and/or travel compensation for activities with Almirall Hermal GmbH, Biogen, Merck, Novartis, Roche, and Sanofi Genzyme, none related to this work. L Diem has received travel grants from Bayer, Biogen, Roche, and Merck, as well as speaker honoraria from Merck. M Briner received travel grants from Merck and Biogen. C Kilidireas has received travel grants and consulting fees from Biogen, Sanofi, Novartis, Roche, Teva, and Serono. L Stefanis has received the following grants: MULTISYN European Program (EU, FP7-HEALTH.2013.1.2-1, number 602646), PPMI (supported by the Michael J. Fox Foundation), IMPRIND-IMI2 Number 116060 (EU, H2020), SANTE 2017 and 2019 Research Grants in Biomedical Sciences, NO-MND (EU-FP7-PEOPLE-2013-IRSES), NPF 2015 Investigator Award (Collaborator), ‘PBMC and urine collection in LRRK2 and idiopathic PD’ Grant by the Michael J. Fox Foundation (Collaborator). He has served on an Advisory Board for Abbvie. He is conducting clinical trials supported by Abbvie and Sanofi. A Chan has received personal compensation for activities with Bayer, Biogen, Genzyme, Merck, Novartis, Roche, and Teva. He received research support from the Swiss National Fonds No. 310030_172952), Genzyme and UCB. He serves on the editorial board for Clinical and Translational Neuroscience and the Journal of International Medical Research. R Hoepner received research and travel grants from Novartis and Biogen Idec. He also received speaker honoraria from Biogen, Novartis, Merck, and Almirall. He is supported by the Swiss MS Society. ME Evangelopoulos has received travel grants and consulting fees from Biogen, Novartis, Teva, Genzyme, Roche, and Merck.
Références
Clin Exp Immunol. 2008 Jan;151(1):42-50
pubmed: 18005364
Front Immunol. 2018 Jul 13;9:1590
pubmed: 30057580
N Engl J Med. 2016 Oct 20;375(16):1552-1565
pubmed: 27797318
Acta Neuropathol. 2017 Jan;133(1):13-24
pubmed: 27988845
J Clin Invest. 1973 Oct;52(10):2629-40
pubmed: 4729056
Int Rev Immunol. 2017 Nov 2;36(6):352-359
pubmed: 28800262
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Lupus. 1997;6(4):390-4
pubmed: 9175025
J Rheumatol. 2015 Feb;42(2):181-7
pubmed: 25593227
N Engl J Med. 2008 Feb 14;358(7):676-88
pubmed: 18272891
Mult Scler. 2015 Jul;21(8):1036-44
pubmed: 25392339
J Pediatr. 1997 Aug;131(2):306-8
pubmed: 9290622
Ther Adv Neurol Disord. 2019 Mar 29;12:1756286419835652
pubmed: 30956685
Hum Immunol. 2016 Jan;77(1):7-11
pubmed: 26429316
Mult Scler. 2013 Oct;19(11):1454-61
pubmed: 23439578
World J Gastrointest Pathophysiol. 2017 May 15;8(2):27-38
pubmed: 28573065
J Neurol. 2018 Oct;265(10):2342-2345
pubmed: 30109480
J Neuroimmunol. 2006 Nov;180(1-2):17-28
pubmed: 16945427
Expert Opin Biol Ther. 2009 Jul;9(7):889-95
pubmed: 19463076
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
J Exp Med. 2012 May 7;209(5):1001-10
pubmed: 22547654
J Immunol. 1976 Jun;116(6):1592-5
pubmed: 944738
Ann Allergy Asthma Immunol. 2007 Sep;99(3):281-3
pubmed: 17910333
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668